The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans

Metabolism: Clinical and Experimental

Volumn 62, Issue 12, 2013, Pages 1840-1849

  Connolly, Beth A ^a,b   O'Connell, Daniel P ^a,b   Lamon Fava, Stefania ^c   Leblanc, Daniel F ^a,b   Kuang, Yu Lin ^c   Schaefer, Ernst J ^c   Coppage, Andrew L ^a   Benedict, Claude R ^b   Kiritsy, Christopher P ^b   Bachovchin, William W ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b Arisaph Pharmaceuticals   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

HDL C; LDL C; Lipid metabolism; TG

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; APOLIPOPROTEIN A1; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NICOTINIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DIET; DRUG ACTIVITY; FEEDING; GENE EXPRESSION; HIGH FRUCTOSE DIET; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER;

ABCA1; ADENOSINE ATP-BINDING CASSETTE A1; AIM-HIGH; APO A-I; APOB48; APOE; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B48; APOLIPOPROTEIN E; ARBITER; ARTERIAL BIOLOGY FOR THE INVESTIGATION OF TREATMENT EFFECTS OF REDUCING CHOLESTEROL; ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES; CETP; CHOLESTERYL ESTER TRANSFER PROTEIN; CLAS; DGAT2; DIACYLGLYCEROL ACYLTRANSFERASE 2; FAMILIAL ATHEROSCLEROSIS TREATMENT STUDY; FATS; FFA; FREE FATTY ACIDS; GOLDEN SYRIAN; GS; HATS; HDL; HDL-ATHEROSCLEROSIS TREATMENT STUDY; HDL-C; HEART PROTECTION STUDY 2-TREATMENT OF HDL TO REDUCE THE INCIDENCE OF VASCULAR EVENTS; HF/HF; HIGH-DENSITY LIPOPROTEIN; HIGH-FAT, HIGH-CHOLESTEROL, AND HIGH-FRUCTOSE; HPS2-THRIVE; LDL; LDL-C; LDLR; LIPID METABOLISM; LIVER X RECEPTOR-ALPHA; LOW-DENSITY LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN RECEPTOR; LXRΑ; NC; NORMAL CHOW; SCAVENGER RECEPTOR CLASS B MEMBER 1.; SR-B1; TC; TG; THE CHOLESTEROL-LOWERING ATHEROSCLEROSIS STUDY; TOTAL CHOLESTEROL; TRIGLYCERIDES; VERY LOW-DENSITY LIPOPROTEIN; VLDL;

ADIPONECTIN; ANIMALS; APOLIPOPROTEINS E; ATP BINDING CASSETTE TRANSPORTER 1; BLOTTING, WESTERN; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CRICETINAE; DIET; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; FRUCTOSE; GENE EXPRESSION; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPOPROTEINS; MALE; MESOCRICETUS; NIACIN; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 84887997665     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.08.001     Document Type: Article

References (55)

1. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin on lipoprotein metabolism Curr Atheroscler Rep 2 1 2000 36 46
2. S.J. Nicholls, K.A. Rye, and P.J. Barter High-density lipoproteins as therapeutic targets Curr Opin Lipidol 16 3 2005 345 349
3. K.G. Berge, and P.L. Canner Coronary drug project: experience with niacin. Coronary Drug Project Research Group Eur J Clin Pharmacol 40 Suppl. 1 1991 S49 S51
4. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 22 2001 1583 1592
5. B.G. Brown, L. Hillger, and X.Q. Zhao Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study Ann N Y Acad Sci 748 1995 407 417 discussion 417-408
6. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial JAMA 284 10 2000 1263 1270
7. D.H. Blankenhorn, S.A. Nessim, and R.L. Johnson Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 23 1987 3233 3240
8. A.J. Taylor, L.E. Sullenberger, and H.J. Lee Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 23 2004 3512 3517
9. T.C. Villines, E.J. Stanek, and P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 24 2010 2721 2726
10. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 24 2011 2255 2267
11. O'Riordan M. HPS-2 THRIVE misses primary end point: no benefit of niacin/laropiprant. Assessed at http://www.theheart.org/article/1490635.do on 20 December 2012.
12. S.J. Nicholls Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med 79 1 2012 38 43
13. A. Wise, S.M. Foord, and N.J. Fraser Molecular identification of high and low affinity receptors for nicotinic acid J Biol Chem 278 11 2003 9869 9874
14. S. Tunaru, J. Kero, and A. Schaub PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat Med 9 3 2003 352 355
15. T. Soga, M. Kamohara, and J. Takasaki Molecular identification of nicotinic acid receptor Biochem Biophys Res Commun 303 1 2003 364 369
16. E. Lai, M.G. Waters, and J.R. Tata Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans J Clin Lipidol 2 5 2008 375 383
17. P.D. Boatman, B. Lauring, and Schrader TO (1aR,5aR)1a,3,5,5a-Tetrahydro- 1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans J Med Chem 55 8 2012 3644 3666
18. Lauring B, Taggart AK, Tata JR, et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 4(148):148ra115.
19. D.M. Capuzzi, J.R. Guyton, and J.M. Morgan Efficacy and safety of an extended-release niacin (Niaspan): a long-term study Am J Cardiol 82 12A 1998 74U 81U discussion 85U-86U
20. S.M. Grundy, G.L. Vega, and M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 14 2002 1568 1576
21. P. Siripurkpong, and K. Na-Bangchang Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells J Nutr Biochem 20 4 2009 261 268
22. T. Rubic, M. Trottmann, and R.L. Lorenz Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin Biochem Pharmacol 67 3 2004 411 419
23. S. Lamon-Fava, M.R. Diffenderfer, and P.H. Barrett Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins Arterioscler Thromb Vasc Biol 28 9 2008 1672 1678
24. F.Y. Jin, V.S. Kamanna, and M.L. Kashyap Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport Arterioscler Thromb Vasc Biol 17 10 1997 2020 2028
25. B.J. Wu, L. Yan, and F. Charlton Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids Arterioscler Thromb Vasc Biol 30 5 2010 968 975
26. M. Lukasova, C. Malaval, and A. Gille Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells J Clin Invest 121 3 2011 1163 1173
27. J.E. Digby, E. McNeill, and O.J. Dyar Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin Atherosclerosis 209 1 2009 89 95
28. S. Westphal, K. Borucki, and E. Taneva Adipokines and treatment with niacin Metabolism 55 10 2006 1283 1285
29. S. Westphal, K. Borucki, and E. Taneva Extended-release niacin raises adiponectin and leptin Atherosclerosis 193 2 2007 361 365
30. S. Westphal, and C. Luley Preferential increase in high-molecular weight adiponectin after niacin Atherosclerosis 198 1 2008 179 183
31. B.R. Krause, and H.M. Princen Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 140 1 1998 15 24
32. E. Holzhauser, C. Albrecht, and Q. Zhou Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities J Cardiovasc Pharmacol 57 4 2011 447 454
33. J.W. van der Hoorn, W. de Haan, and J.F. Berbee Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice Arterioscler Thromb Vasc Biol 28 11 2008 2016 2022
34. J. Otto, J.M. Ordovas, and D. Smith Lovastatin inhibits diet induced atherosclerosis in F1B Golden Syrian hamsters Atherosclerosis 114 1 1995 19 28
35. P.R. Wang, Q. Guo, and M. Ippolito High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists Eur J Pharmacol 427 3 2001 285 293
36. R.A. Srivastava, and S. He Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster Mol Cell Biochem 345 1-2 2010 197 206
37. W. Innis-Whitehouse, X. Li, and W.V. Brown An efficient chromatographic system for lipoprotein fractionation using whole plasma J Lipid Res 39 3 1998 679 690
38. H. Basciano, L. Federico, and K. Adeli Fructose, insulin resistance, and metabolic dyslipidemia Nutr Metab (Lond) 2 1 2005 5
39. K.L. Stanhope, J.M. Schwarz, and N.L. Keim Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans J Clin Invest 119 5 2009 1322 1334
40. Y. Nakashima, A.S. Plump, and E.W. Raines ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler Thromb 14 1 1994 133 140
41. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 2 1996 213 219
42. W. Hochholzer, D.D. Berg, and R.P. Giugliano The facts behind niacin Ther Adv Cardiovasc Dis 5 5 2011 227 240
43. Q. Guo, P.R. Wang, and D.P. Milot Regulation of lipid metabolism and gene expression by fenofibrate in hamsters Biochim Biophys Acta 1533 3 2001 220 232
44. R.S. Birjmohun, B.A. Hutten, and J.J. Kastelein Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2 2005 185 197
45. R.R. Singaraja, V. Bocher, and E.R. James Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1 J Biol Chem 276 36 2001 33969 33979
46. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 12 2006 3090 3100
47. L.H. Zhang, V.S. Kamanna, and S.H. Ganji Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells J Lipid Res 53 5 2012 941 950
48. L. Yvan-Charvet, J. Kling, and T. Pagler Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 7 2010 1430 1438
49. E.P. Plaisance, P.W. Grandjean, and B.L. Brunson Increased total and high-molecular weight adiponectin after extended-release niacin Metabolism 57 3 2008 404 409
50. O. Renaldi, B. Pramono, and H. Sinorita Hypoadiponectinemia: a risk factor for metabolic syndrome Acta Med Indones 41 1 2009 20 24
51. Y. Zhang, R.J. Schmidt, and P. Foxworthy Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A Biochem Biophys Res Commun 334 2 2005 729 732
52. S.H. Ganji, S. Tavintharan, and D. Zhu Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J Lipid Res 45 10 2004 1835 1845
53. F. Montecucco, A. Quercioli, and F. Dallegri New evidence for nicotinic acid treatment to reduce atherosclerosis Expert Rev Cardiovasc Ther 8 10 2010 1457 1467
54. S. Offermanns, S.L. Colletti, and T.W. Lovenberg International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B) Pharmacol Rev 63 2 2011 269 290
55. R.P. Giugliano Niacin at 56 years of age - time for an early retirement? N Engl J Med 365 24 2011 2318 2320